Dr Reddy’s CEO: We’re In ‘Great Dialogue’ With The Innovation Industry In China
Executive Summary
Dr Reddy’s is collaborating with innovator firms in China, Israel and the US largely in areas of unmet need, propelling its “Horizon-2” strategy that encompasses segments like biologics and cell and gene therapy, digital services and immuno-oncology NCEs, among others.
You may also be interested in...
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.
Glenmark Leaps Into Sub-Q Checkpoint Inhibitor Terrain With China Deal
India-China combine for subcutaneously injected PD-L1 inhibitor takes wings, with Glenmark set to take Alphamab/3D Med’s envafolimab to key emerging markets, widening access for patients.
Trends Shaping India Pharma: Next-Gen Therapies, Adjacencies, LOE Strategies And More
The arrival of an indigenous CAR-T cell therapy, a shot at GLP-1s and Parkinson’s disease, strides into adjacencies and an “easy revenue stream” formula for products set to lose exclusivity are some of the striking developments seen playing out in India. Industry leaders, including Cipla’s CEO, share their views with Scrip on some of the key trends in the first instalment of this two-part roundup.